Sandoz Launches Pyzchiva (Biosimilar, Ustekinumab-ttwe) in the US for Chronic Inflammatory Diseases
Shots:
- Sandoz has launched Pyzchiva, a biosimilar version of Stelara in the US to treat mod. to sev. plaque PsO & active PsA in adults as well as pediatric pts, plus mod. to sev. active crohn’s disease & UC in adults; expected to offer interchangeability by H1'25
- Launch follows Samsung’s settlement & license deal with J&J for the US market & commercialization agreement with Sandoz in Sep 2023. As per the Sep 2023 deal, Sandoz can market Pyzchiva in the US, Canada, EEA, Switzerland, UK & Brazil, while Samsung handles development, IP, manufacturing & supply
- Pyzchiva is a fully human anti-IL-12/IL-23 mAb that is available in pre-filled syringes (45mg/0.5mL & 90mg/mL) & single-dose vials (IV: 130mg/26 mL & SC: 45mg/0.5 mL)
Ref: Sandoz | Image: Sandoz
Related News:- Sandoz Report the EC’s Approval of Afqlir (Biosimilar, Eylea) to Treat Neovascular Age-related Macular Degeneration (nAMD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
